


See "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies" on page 475-486.



Supplementary Fig. 4. Corticosteroid-free remission at week 44 of the maintenance study. ^a $P=0.035$ vs. placebo but only nominally significant per the hierarchical testing procedure; ^b $P=0.004$ vs. placebo. q12w, every 12 weeks; q8w, every 8 weeks.